CA-NETAPP
16.3.2022 13:02:09 CET | Business Wire | Press release
NetApp (NASDAQ: NTAP), a global, cloud-led, data-centric software company, together with Cisco (NASDAQ: CSCO), today announced the evolution of FlexPod with the introduction of FlexPod® XCS, providing one automated platform for modern applications, data and hybrid cloud services.
FlexPod is composed of pre-validated storage, networking, server technologies from Cisco and NetApp. The new FlexPod XCS platform is designed to accelerate the delivery of modern applications and data in a hybrid cloud environment. FlexPod XCS is the first and only hybrid cloud solution natively integrated across all three major public cloud providers. Additionally, organizations will have the option to use FlexPod-as-a-Service, a pay-as-you-grow pricing model for financial and operational flexibility.
“For years, FlexPod has been helping Presidio customers increase app performance, save software Capex, and decrease unplanned downtime incidents,” said Raphael Meyerowitz, vice president, Engineering at Presidio. “With FlexPod XCS, NetApp and Cisco are providing more flexibility, accessibility and scalability to our customers to deliver a seamless hybrid cloud experience.”
“It is great seeing Cisco and NetApp launching FlexPod XCS together in this hybrid cloud era,” said Jeffrey den Oudsten, Chief Technology Officer at Conscia Netherlands. “Standardization on FlexPod XCS brings rich technologies and huge benefits for us and our customers in various ways, with ability to deliver one point for billing, ordering, support and validated designs. Conscia is determined to facilitate the best hybrid cloud infrastructure for its customers, and together with Cisco and NetApp, we have the best-in-class technology partners helping us to deliver on that promise.”
FlexPod XCS simplifies hybrid cloud operations by increasing accessibility and scalability, extending the infrastructure from an on-premises and edge standard to the hybrid cloud. This new offering lays the groundwork for continued joint innovation that will bring new solutions to market for hybrid cloud, containers, and modern workloads.
FlexPod XCS provides a new set of capabilities to the FlexPod platform:
- Hybrid Cloud Connectivity: By extending organizations’ data fabric, customers gain the operational certainty of putting the right apps and data in the right place at the right time.
- Automation: Comprehensive infrastructure automation across all lifecycle phases using Cisco Intersight™ Cloud Orchestrator and NetApp automated scripts and workflows to simplify day-to-day IT operations including configuration, deployment, expansion, and infrastructure consumption and optimization.
- Visibility: Providing an enhanced and unified view of all FlexPod components through Cisco Intersight, enabling organizations to respond to their business needs more quickly with more intelligent resource decisions
- FlexPod-as-a-Service: Lowering initial costs for flexibility and tailoring purchasing options based on budgets and usage
- New Reference Architecture with NetApp Cloud Volumes ONTAP ® (CVO) instances in AWS: FlexPod XCS and ONTAP integration with automation via Cisco Intersight
FlexPod XCS also allows IT departments to gain new insights with full-stack visibility and customized automation capabilities that increase operational productivity. The new FlexPod-as-a-Service consumption model enables customers to have more financial and operational flexibility by aligning costs based on usage.
"Our strategic relationship with NetApp continues to create value for businesses through deep technology integration aimed at solving our customers' biggest challenges,” said Siva Sivakumar, Vice President, Cloud & Compute Product Management, Cisco. “FlexPod XCS powered by Cisco Intersight delivers key new capabilities for our customers such as automation, visibility and hybrid cloud operations into a single unified platform for modern apps, data, and hybrid cloud services.”
“We are proud of our continued innovation with Cisco as we expand FlexPod’s capabilities that solve for organizations’ unique business challenges,” said Mike Arterbury, Vice President, Hybrid Cloud Infrastructure & OEM Solutions at NetApp. “Building on our twelve-year partnership with Cisco, FlexPod XCS combines our best-in-class technologies to simplify the delivery of data and applications, enabling enterprises to run new services more efficiently at the edge, core or in the cloud.”
FlexPod® XCS is in preview for partners and customers and is expected to be generally available globally in mid-2022.
Additional Resources:
- NetApp Blog: FlexPod XCS Extends the FlexPod Infrastructure Standard to the Hybrid Cloud
- Cisco Blog: Cisco and NetApp introduce FlexPod XCS to simplify and accelerate customers’ hybrid cloud journeys
- Learn more about FlexPod XCS and the Cisco-NetApp Partnership
- FlexPod.com
About FlexPod
Trusted by thousands of customers across the globe, the enhanced FlexPod XCS platform brings a new level of visibility and automation that can help propel customers’ journey into hybrid cloud operations. Composed of prevalidated storage, networking and server technologies, and management software, FlexPod® XCS is designed to increase IT responsiveness to organizational needs providing intelligent insights to optimize costs and performance, support deployment decisions with cloud-like consumption models, and maintain existing configurations across FlexPod infrastructure. By simplifying the delivery of data and applications, enterprises have an advantage of running new services and workloads at the edge, core, or in the cloud.
FlexPod® XCS pricing is mapped to Cisco Intersight Advantage and Premier Tiers and current FlexPod pricing.
About NetApp
NetApp is a global cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter , LinkedIn , Facebook , and Instagram .
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
Many of the products and features described herein remain in varying stages of development and will be offered on a when-and-if-available basis. The delivery timeline of these products and features is subject to change at the sole discretion of Cisco or NetApp, and neither Cisco nor NetApp will have liability for delay in the delivery or failure to deliver any of the products or features set forth in this document.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316005269/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
